Insider Selling: Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Sells 12,726 Shares of Stock

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) CEO Eric D. Shaff sold 12,726 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $0.81, for a total transaction of $10,308.06. Following the completion of the transaction, the chief executive officer now directly owns 192,039 shares of the company's stock, valued at approximately $155,551.59. This trade represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Seres Therapeutics Stock Down 1.0 %

MCRB traded down $0.01 during trading hours on Friday, reaching $0.80. 906,745 shares of the company's stock traded hands, compared to its average volume of 1,641,410. The firm has a 50-day moving average price of $0.84 and a 200 day moving average price of $0.85. The firm has a market capitalization of $137.19 million, a PE ratio of -3.49 and a beta of 2.11. Seres Therapeutics, Inc. has a 52-week low of $0.54 and a 52-week high of $1.53.

Institutional Trading of Seres Therapeutics

A number of large investors have recently made changes to their positions in MCRB. Avantax Advisory Services Inc. boosted its holdings in shares of Seres Therapeutics by 170.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 28,500 shares during the period. Jane Street Group LLC grew its position in shares of Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after buying an additional 37,866 shares in the last quarter. Virtu Financial LLC increased its stake in shares of Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock valued at $56,000 after buying an additional 18,191 shares during the period. Providence Wealth Advisors LLC raised its holdings in shares of Seres Therapeutics by 29.2% in the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock valued at $93,000 after acquiring an additional 22,250 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock valued at $218,000 after acquiring an additional 44,461 shares in the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MCRB. Chardan Capital reaffirmed a "buy" rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. downgraded Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research report on Thursday, October 24th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $10.00 price objective on shares of Seres Therapeutics in a research note on Thursday, November 14th. Finally, StockNews.com raised shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $5.08.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.